Single-molecule assays have, by definition, the ultimate sensitivity and represent the next frontier in biological analysis and diagnostics. However, many of these powerful technologies require dedicated laboratories and trained personnel and have therefore remained research tools for specialists. Here, we present a single-molecule confocal system built from a 3D-printed scaffold, resulting in a compact, plug and play device called the AttoBright. This device performs single photon counting and fluorescence correlation spectroscopy (FCS) in a simple format and is widely applicable to the detection of single fluorophores, proteins, liposomes or bacteria. The power of single-molecule detection is demonstrated by detecting single α-synuclein amyloid fibrils, that are currently evaluated as biomarkers for Parkinson's disease, with an improved sensitivity of >100,000-fold over bulk measurements.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6906517 | PMC |
| http://dx.doi.org/10.1038/s41467-019-13617-0 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Biomarkers.
Alzheimers Dement
December 2024
Clinical Neurochemistry Laboratory Sahlgrenska University Hospital, Mölndal, Sweden.
Background: This research introduces a novel method for quantifying aggregated tau in body fluids, specifically cerebrospinal fluid (CSF), aiming to enhance the diagnosis and monitoring of neurodegenerative diseases, with a focus on Alzheimer's disease (AD).
Method: By combining tau protein amplification with a highly sensitive single-molecule array (Simoa) immunoassay using an anti-tau antibody CT19.1 in a homogenous manner, the approach enables precise measurements of tau aggregates in CSF.
Biomarkers.
Alzheimers Dement
December 2024
Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Background: Plasma tau phosphorylated at threonine 231 (p-tau231) is a promising novel biomarker of emerging Alzheimer's disease (AD) pathology. We aimed to characterize cross-sectional and longitudinal plasma p-tau231 measurements and estimated ages of biomarker onset in an exceptionally large number of presenilin (PSEN1) E280A (Glu280Ala) mutation carriers and age-matched non-carriers from the Colombian autosomal dominant Alzheimer's disease kindred.
Method: We included a cohort of 722 PSEN1 E280A mutation carriers (mean age 36.
Biomarkers.
Alzheimers Dement
December 2024
University of Fribourg, Adolphe Merkle Institute, Fribourg, Switzerland.
Background: Tau protein phosphorylation and aggregation are the pathological hallmarks of Alzheimer's disease (AD) and other tauopathies. Multiple phosphorylation sites in Tau protein at serine (S), threonine (T), and tyrosine result in high heterogeneity and enhanced aggregation kinetics.
Method: Here, we used nanopores coated with a fluid lipid bilayer to characterize native and hyperphosphorylated Tau proteins on a single-molecule level.
Biomarkers.
Alzheimers Dement
December 2024
Department of Psychiatry, School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA.
Background: The detection and monitoring of Alzheimer's disease (AD) biomarkers in plasma are crucial for early diagnosis and prognosis. However, the stability of plasma AD biomarkers can be compromised by the degradation caused by endogenous proteases present in blood. The efficacy of protease inhibitors in mitigating this degradation is yet to be established.
View Article and Find Full Text PDFBiomarkers.
Alzheimers Dement
December 2024
Centre for Brain Research, University of Auckland, Auckland, New Zealand.
Background: Single molecule array (Simoa) technology enables the detection of Alzheimer's disease (AD) neuropathology in blood. This study compared cross-sectional biomarker profiles for participants from the New Zealand-Dementia Prevention Research Clinics (NZ-DPRCs) who spanned the continuum from healthy older adults to a clinical diagnosis of AD.
Method: NZ-DPRC participants were clinically classified as cognitively unimpaired adults (CU, n=34), subjective cognitive decline (SCD, n=65), non-amnestic mild cognitive impairment (single and multi-domain, non-aMCI, n= 23), amnestic MCI (single and multi-domain, aMCI, n=104), and AD (n=27).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!